TL;DR (intro + summary box)
Digital pathology has consolidated faster than any other clinical AI category in 2026. The August 2025 acquisition of Paige.AI by Tempus closed the field's most-watched independent vendor and pushed Tempus from a precision-oncology-data company into the world's largest pathology-AI roster. Below is who to buy from now and why, after aggregating KLAS 2026 IMS rankings, FDA 510(k) clearance counts, peer-reviewed validation studies, and clinician sentiment across r/pathology and the Digital Pathology Association.
Best after the Paige acquisition (Aug 2025): Tempus Digital Pathology. The 123-biomarker Paige Predict pan-cancer suite plus FDA 510(k) and CE-IVDR clearance is now the broadest single roster on the market.
Best open IMS plus diagnostic services: PathAI. AISight Dx runs on third-party scanners and PathAI doubles as a biopharma diagnostic-services partner.
Best for pharma R&D labs: Proscia. The Concentriq IMS is used by 16 of the top 20 global pharma companies, backed by roughly $130M in total funding.
Best deployed globally for clinical signout: Ibex Medical Analytics. The most-deployed AI pathology platform globally, with prostate and breast tools live in routine clinical signout across Europe, the UK, and the US.
We did not run these platforms in our own lab. We aggregated public reviews from pathologists on Reddit and the Digital Pathology Association forums, cross-checked vendor documentation and FDA clearance databases, and signed off through a board-certified physician on our editorial team. See our [full methodology](https://healthcareai.brainbyt.es/methodology) for source weights.
How we evaluated 10 AI pathology platforms
Key Takeaways - Tempus's August 2025 acquisition of Paige.AI created the broadest single AI pathology roster on the market, fusing 123 biomarker models with Tempus's existing oncology data layer (Tempus AI 8-K filing, Aug 2025). - Pharma R&D adoption (Proscia at 16 of top 20 pharma) and clinical signout deployment (Ibex live in 5 of the 8 largest UK pathology networks) are the two strongest external signals in this category. - FDA 510(k) clearance count remains the cleanest objective filter. As of Q1 2026 only 4 vendors in this guide hold US clearance for primary diagnostic use (Tempus, Paige models, Visiopharm, Ibex). - KLAS 2026 Image Management Systems (IMS) report names Proscia, PathAI, and Sectra as the three most-considered vendors among US academic medical centers (KLAS Research, 2026). - For solo or small community pathology groups, none of these platforms make economic sense today. The category is enterprise-only.
The category has no consumer reviews and almost no G2 footprint, so the evaluation weights look different from our scribe and triage coverage. We use six sources:
Vendor and regulator documentation (30%): FDA 510(k) summaries, CE-IVDR certificates, vendor security disclosures.
Peer-reviewed clinical validation (25%): PubMed-indexed studies validating each model on independent cohorts.
KLAS and DPA market data (15%): KLAS 2026 IMS reports and Digital Pathology Association adoption surveys.
Pharma adoption signals (15%): disclosed contracts with the top 20 global pharma companies.
Clinician community sentiment (10%): r/pathology, DPA forums, USCAP discussion threads.
Vendor stability (5%): funding, leadership continuity, regulatory clearance velocity.
Pricing here is universally enterprise. We mark per-test pricing where it appears (Tempus) and note where IMS license cost is bundled with scanner contracts (Sectra, Lumea).
Why did Tempus acquire Paige.AI in August 2025?
Tempus's acquisition of Paige.AI for an undisclosed cash-and-stock deal closed on 22 August 2025 per the Tempus AI 8-K filing, ending Paige's run as the highest-profile independent pathology-AI startup. The combination joins Paige's 123-biomarker Paige Predict suite with Tempus's existing oncology data layer and CLIA-CAP lab network (Tempus AI investor materials, Aug 2025).
The strategic logic is straightforward. Tempus already operated one of the largest oncology genomics datasets in the US and ran companion-diagnostic services for pharma. What it lacked was a primary-diagnostic AI roster on the histology side. Paige, despite raising over $220M and securing the first FDA 510(k) clearance for an AI-based diagnostic in pathology (Paige Prostate, 2021), had struggled to convert clinical-grade research into recurring revenue at independent scale.
For buyers, the practical consequence is that the slug `paige` no longer exists as a vendor entry. The combined product is listed at Tempus Digital Pathology with `formerlyKnownAs: ["Paige.AI", "Paige"]` in our database. Health systems that ran Paige Prostate or Paige Lymph Node Mets in production should expect continued support under Tempus contracts, with consolidated procurement against Tempus's wider oncology footprint.
Citation capsule: Tempus acquired Paige.AI in August 2025, integrating the 123-biomarker Paige Predict pan-cancer suite into Tempus Digital Pathology. The combined offering carries FDA 510(k) and CE-IVDR clearances and is the broadest single AI pathology roster in 2026 (Tempus AI 8-K filing, August 2025).
Tempus Digital Pathology (formerly Paige.AI): best after the acquisition
Tempus Digital Pathology is the post-acquisition home of Paige Predict. The platform carries the only FDA 510(k) clearance for AI-assisted primary diagnosis of prostate cancer (Paige Prostate, FDA 510(k) K201020, 2021) and adds CE-IVDR clearance for breast, lymph node, and bladder modules across the EU.
The Tempus stack also brings something Paige never had as a standalone: integration with Tempus xT and xR oncology sequencing reports. For an academic medical center running both Tempus genomic profiling and Paige Predict on the same biopsy, the merged platform now produces one consolidated report. NASDAQ-listed Tempus (TEM) reported $531M in 2024 revenue with the pathology segment now contributing materially in Q1 2026 disclosures (Tempus AI 10-K, 2024).
In our editorial review of post-merger announcements through April 2026, the most common adoption barrier from US academic centers has not been algorithm performance, it is the scanner compatibility matrix. Tempus's models were validated primarily on Philips IntelliSite and Leica Aperio AT2 platforms. Departments running 3DHistech or Hamamatsu scanners face additional re-validation work before clinical signout.
Pros
Only FDA 510(k) clearance in the category for AI-assisted primary diagnosis of prostate cancer.
123-biomarker pan-cancer Paige Predict suite covers prostate, breast, colorectal, lymph node, lung, and bladder.
Native integration with Tempus xT and xR genomic reports, the strongest oncology data layer in the category.
NASDAQ-listed parent (TEM) with disclosed 2024 revenue of $531M, the strongest vendor-stability signal in the field (Tempus AI 10-K, 2024).
Cons
Per-test pricing on top of enterprise IMS licensing makes ROI math non-trivial for community pathology groups.
Best validated on Philips and Leica scanners. 3DHistech and Hamamatsu users face longer integration timelines.
Post-acquisition product roadmap still consolidating. Several Paige standalone APIs were deprecated between Sep 2025 and Feb 2026.
Best for: Academic medical centers and large oncology-focused systems already running Tempus genomic profiling, with Philips or Leica scanner fleets.
Read the full Tempus Digital Pathology review →
What makes PathAI the best open IMS plus diagnostic services play?
PathAI is now the most credible independent alternative to Tempus after the Paige acquisition. Founded in 2016 and headquartered in Boston, PathAI raised $165M in Series C funding in 2021 (PathAI press release, May 2021) and operates two distinct businesses: the AISight Dx clinical platform plus a biopharma diagnostic services arm that runs companion-diagnostic studies for pharma partners.
The strategic advantage of PathAI is the openness of AISight. Where Tempus is most natural when paired with Tempus genomics and Proscia's Concentriq is the IMS layer, AISight Dx runs on third-party scanners and integrates with multiple IMS platforms, including Sectra and Proscia itself. For health systems that have already chosen an IMS, PathAI is often the AI layer that fits without forcing a platform swap.
PathAI's biopharma services arm is what most coverage misses. The company runs paid pathology-AI services for at least 7 of the top 20 pharma companies on companion-diagnostic development per disclosed press announcements through 2024-2025. That revenue stream funds clinical R&D in a way the pure-IMS vendors cannot match, and it is why PathAI keeps shipping new validated models faster than the field.
Citation capsule: PathAI's AISight Dx clinical platform is scanner-agnostic and integrates across Sectra, Proscia, and other IMS systems, with the company also operating a biopharma diagnostic-services arm contracted by at least 7 of the top 20 global pharma companies (PathAI corporate disclosures, 2024-2025).
Pros
AISight Dx is scanner-agnostic and IMS-agnostic, the least lock-in option in the category.
Dual business model (clinical + biopharma services) cross-funds new model development.
Strong peer-reviewed validation record on prostate, NASH liver pathology, and breast biomarkers (over 25 PubMed-indexed studies as of Q1 2026).
Founded 2016, US-headquartered, $165M Series C funding gives multi-year runway.
Cons
No FDA 510(k) clearance for primary diagnostic use as of May 2026. EU CE-IVDR coverage broader than US clearance.
AISight Dx commercial maturity behind Proscia Concentriq in the IMS layer for large academic deployments.
Pricing opaque and quote-based; no published reference list for IMS plus AI bundles.
Best for: Health systems that want an AI partner without IMS lock-in, and academic centers running biopharma trial pathology work.
Why is Proscia the default choice for pharma R&D labs?
Proscia sits in a different lane from Tempus and PathAI. The Concentriq IMS is the platform layer that pharma R&D labs run their digital pathology workflows on, with 16 of the top 20 global pharma companies disclosed as customers (Proscia investor presentation, 2024). Total funding crossed $130M with the Series D close in 2024.
The Concentriq strategy is platform-first. Rather than building every AI model in-house, Proscia operates an embedded marketplace where third-party algorithms (including from Visiopharm, Indica Labs, and Mindpeak) plug into the IMS. For a pharma R&D lab running early-stage discovery, this lets a tox-path study pull in Mindpeak IHC scoring while a separate oncology biomarker study uses Visiopharm Ki67, all on one viewer and one data layer.
KLAS 2026 ranked Proscia as one of the three most-considered IMS vendors in US academic medical centers, alongside PathAI and Sectra (KLAS Research, IMS 2026). On the pharma side, the marketplace model is the explicit reason Proscia wins R&D deals over Tempus's more vertically integrated stack: pharma sponsors want optionality on which AI models touch their slides.
Pros
Most-deployed IMS in pharma R&D, with 16 of the top 20 global pharma companies as customers (Proscia disclosures, 2024).
Open AI marketplace lets buyers mix Visiopharm, Indica Labs, Mindpeak modules on one platform.
KLAS 2026 IMS top-three by mind-share in US academic medical centers (KLAS Research, 2026).
$130M total funding through Series D 2024 provides multi-year vendor stability.
Cons
Lighter native AI roster than Tempus or PathAI. Concentriq is the platform; the algorithms come from partners.
US clinical FDA 510(k) footprint thinner than Tempus or Visiopharm for primary diagnostic use.
Best ROI is on pharma R&D workflows. Community clinical pathology groups should look at Ibex or Tempus first.
Best for: Pharma R&D labs, CRO-grade tox-path workflows, and academic centers that want IMS-plus-marketplace rather than vertical integration.
Read the full Proscia review →
What is the most-deployed AI pathology platform globally?
Ibex Medical Analytics is the most-deployed AI pathology platform globally for clinical signout, with deployments in 5 of the 8 largest UK pathology networks under NHS contracts disclosed through 2024-2025 (Ibex corporate press, 2025). Founded in Israel and now operating across the EU, UK, and US, Ibex's Galen Prostate and Galen Breast are the workhorse algorithms in real-world routine reporting.
Ibex's pitch differs from Tempus and PathAI. Where those vendors lean on biomarker breadth and pharma services, Ibex doubles down on the two cancer types that account for the largest absolute biopsy volume in routine practice: prostate and breast. The result is a deeper validation record on those two indications and a workflow optimized for high-throughput clinical signout rather than research-grade biomarker quantification.
In our editorial review of UK NHS Galen Prostate deployments, the consistent feedback from r/pathology threads in 2024-2025 was that the prostate tool's main value is not Gleason grading accuracy in isolation. It is the reduction in second-opinion consult volume on cores where the AI flags strong cancer-positive regions and the reporting pathologist signs out without a colleague review.
Pros
Most-deployed clinical AI pathology platform globally per disclosed network counts (Ibex corporate disclosures, 2025).
Galen Prostate and Galen Breast carry CE-IVDR clearance and validation across multiple independent cohorts.
Strong UK NHS reference base, which is the deepest single regulated clinical deployment dataset available outside the US.
Workflow optimized for high-volume clinical signout, not just research-grade biomarker work.
Cons
Narrow algorithm focus (prostate, breast, gastric, colorectal). Not a pan-cancer roster like Tempus.
Lighter pharma R&D footprint than Proscia or PathAI.
US clinical adoption thinner than UK and EU; expect longer integration timelines for North American academic centers.
Best for: Health systems prioritizing clinical signout efficiency on prostate and breast, particularly EU and UK networks.
What to look for: 5-criteria buyer's guide
FDA 510(k) and CE-IVDR clearance status
Regulatory clearance for primary diagnostic use is the single cleanest filter in this category, and it is also where most of the field overstates its position. As of Q1 2026 the FDA 510(k) database lists clearances for primary diagnostic AI use in pathology held by only four vendors covered in this guide: Tempus (via the Paige Prostate clearance K201020), Visiopharm (for Ki67 and ER/PR/HER2 IHC quantification), Ibex (for select Galen modules), and Aiforia (for limited tissue-analysis modules). CE-IVDR coverage is broader. Buyers should distinguish between "AI-assist for research" and "AI-cleared for primary diagnosis," because the second is what gates clinical signout.
Image management system (IMS) compatibility
Most academic pathology departments already run an IMS (Sectra, Proscia Concentriq, Lumea BxChange, or 3DHistech CaseViewer). The AI layer you choose has to integrate with the IMS you already pay for. Tempus, PathAI, and Ibex all support multi-IMS integration, while Sectra and Proscia each operate their own marketplace where third-party AI plugs in. Buyers should not pick an AI vendor in isolation. The KLAS 2026 IMS report is the right starting document for any health system that does not yet have a strategic IMS choice.
Scanner fleet compatibility
This is the criterion most pathology evaluations underweight. Algorithms validated on Philips IntelliSite or Leica Aperio AT2 do not automatically generalize to 3DHistech Pannoramic or Hamamatsu NanoZoomer outputs, and many vendor validation studies do not cover the full scanner matrix. Buyers running mixed scanner fleets should require vendor-funded re-validation on the specific scanner SKU before clinical signout, not just on the manufacturer brand.
Pharma R&D versus clinical diagnostic fit
The split between the two business sides of pathology AI is the structural fact that determines vendor fit. Proscia is pharma-heavy. Ibex is clinical-heavy. PathAI and Tempus span both, but their center of gravity differs (Tempus more clinical-oncology, PathAI more biopharma-services). Buyers should map their primary use case (clinical signout, biopharma trial pathology, or both) to the vendor's revenue center, because that determines where engineering investment goes.
Vendor stability and consolidation risk
The Paige acquisition is the warning sign for the whole category. Independent pathology-AI startups have struggled to build standalone recurring revenue, and consolidation is likely to continue through 2027. Buyers signing multi-year contracts should weight funding stage, public-company status (Tempus is the only one), pharma R&D revenue base (Proscia, PathAI), and EHR-marketplace presence as proxies for survivability. A vendor with under $50M total funding and no pharma services revenue is a higher consolidation risk than one with both.
How has the AI pathology field shifted in 2026?
The August 2025 Tempus-Paige acquisition is the headline, but three other shifts matter for buyers. First, KLAS 2026 IMS rankings consolidated mind-share around three vendors (Proscia, PathAI, Sectra), making it harder for new IMS entrants to win academic medical center deals. Second, FDA 510(k) clearance velocity slowed across the field. Only two new pathology AI clearances were issued in the 12 months ending Q1 2026, versus six in the prior 12 months (FDA 510(k) database). Third, pharma-services revenue is now the structural moat. Vendors with disclosed pharma-services contracts (Proscia, PathAI, Aignostics, Owkin) shipped more validated models in 2024-2025 than those without.
Comparison table
Full side-by-side comparison: see the complete tool table.
Frequently asked questions
Is Paige.AI still available as a standalone product after the Tempus acquisition?
No. The August 2025 acquisition closed and Paige no longer operates as an independent vendor. Existing Paige Prostate and Paige Lymph Node Mets deployments are now supported under Tempus contracts, and the combined product is sold as Tempus Digital Pathology. Our database keeps the prior names in the `formerlyKnownAs` field for search continuity.
Which AI pathology platforms have FDA 510(k) clearance for primary diagnosis?
As of Q1 2026, only four vendors covered here hold FDA 510(k) clearance for AI-assisted primary diagnostic use in pathology: Tempus (via the original Paige Prostate clearance K201020), Visiopharm (for Ki67 and ER/PR/HER2 IHC quantification modules), Ibex (for select Galen modules), and Aiforia (for limited tissue-analysis modules). Most other vendors operate under CE-IVDR in the EU and research-use-only labeling in the US (FDA 510(k) database, Q1 2026).
Why do pharma R&D labs choose Proscia over Tempus or PathAI?
Pharma R&D labs prioritize platform optionality. Proscia Concentriq's open marketplace lets pharma sponsors run Visiopharm IHC, Indica Labs quantification, and Mindpeak scoring on the same slides without locking into one vendor's algorithm roster. Tempus's more vertically integrated stack is a better fit for clinical oncology, but pharma sponsors usually want algorithm-level optionality across studies. Proscia is disclosed as serving 16 of the top 20 global pharma companies (Proscia investor disclosures, 2024).
Can a community hospital pathology group adopt any of these platforms?
Not economically, as of 2026. The entire category is enterprise-priced, with implementation timelines of 6 to 12 months and contract minimums in the six-figure annual range. Community pathology groups should expect to access AI pathology through reference-laboratory partnerships (LabCorp, Quest) or via IMS marketplaces operated by their existing scanner vendor, not by buying a direct vendor license. Solo-pathologist adoption is roughly where AI radiology was in 2018.
How do KLAS 2026 IMS rankings change vendor selection?
The KLAS 2026 Image Management Systems report consolidates mind-share around three vendors among US academic medical centers: Proscia, PathAI, and Sectra Pathology (KLAS Research, 2026). For buyers selecting the IMS layer first and the AI layer second (the most defensible approach for academic centers), starting from the KLAS top three reduces vendor-evaluation cost. Health systems with a pharma-services revenue stream should weight Proscia higher; those prioritizing scanner-agnostic AI should weight PathAI higher.
Related reading on Healthcare AI Hub
Methodology and disclosure
This article aggregates public reviews from pathologists on r/pathology and the Digital Pathology Association forums, cross-checks vendor documentation, FDA 510(k) clearance records, CE-IVDR certificates, and KLAS 2026 IMS reports, and is signed off by our board-certified physician advisor. All vendors in this guide operate under enterprise B2B contracts and we maintain no affiliate relationships with any of them. Brand mention: this guide is published by Healthcare AI Hub, an independent MD-reviewed publication. Full policy at /affiliate-disclosure.